OP Management Invests Widely
OP Asset Management Diversifies Portfolio with New Stakes in Disney, Newmont, and Pharma Giants
Key Points
Disney's stock shows a high level of institutional ownership, with 65.71% of shares held by institutional investors and hedge funds, highlighting broad professional involvement in the company.
OP Asset Management's new stake in Walt Disney is complemented by the presence of other major funds, indicating continued heavy institutional interest in Disney.
In Newmont, OP Asset Management acquired 112,008 shares valued at about $12.125 million, and institutional ownership in the stock stands at 68.85%.
Bristol Myers Squibb insider activity included EVP David V. Elkins selling 30,000 shares on April 1 at an average price of $61.67, reducing his direct stake.
Pfizer's week featured notable milestones, including FDA advancement for an expanded IBRANCE regimen in metastatic breast cancer, a Phase 3 path for a pediatric pneumococcal vaccine, and a $0.43 quarterly dividend.
Finnish institutional giant OP Asset Management Ltd. deployed roughly $87.5 million across five major U.S. companies in the first quarter of 2026, filing a Form 13F with the SEC on April 10 to disclose the new positions. The fund — which manages about $106.2 billion in assets — entered Walt Disney, Newmont, Bristol Myers Squibb, Pfizer, and Applied Industrial Technologies in a single sweep, signaling a deliberate rotation into blue-chip, dividend-paying stocks with high institutional ownership.
The purchases span five distinct sectors: consumer media, gold mining, biopharmaceuticals, and industrial technology. Each company already carries heavy institutional backing, with ownership rates ranging from 65% to over 93% of shares held by funds and professional investors.
Disney and Newmont Attract Fresh Nordic Capital
OP Asset Management bought 182,773 Disney shares for about $17.6 million, joining a wave of institutional buyers piling into the stock. Disney carries 65.71% institutional ownership, according to MarketBeat, with some aggregate counts running as high as 87%. The company is also undergoing a leadership change: Josh D'Amaro, currently head of Disney's Experiences segment, is set to succeed Bob Iger as CEO after the March 2026 handoff. Analysts at Rosenblatt Securities have a $126 price target on the stock, while Barclays sits even higher at $135.
In gold mining, the fund picked up 112,008 Newmont shares worth roughly $12.1 million. Institutional ownership in Newmont stands at 89.28%. Newmont reported record Q1 earnings on April 23 and expanded its share repurchase program, according to Newmont Investor Relations. Newmont shares have risen more than 80% between June 2025 and June 2026, driven by strong gold prices and the completed integration of its Newcrest acquisition.
Pfizer's FDA Win Validates OP's $28 Million Bet
The fund's largest single purchase was 1,002,505 Pfizer shares valued at about $28.15 million. The timing has proven fortuitous. On June 24, the FDA approved Pfizer's IBRANCE regimen for "double positive" metastatic breast cancer. Pfizer EVP Aamir Malik said: "IBRANCE becomes the first and only CDK4/6 inhibitor indicated for patients with HR+ metastatic breast cancer regardless of HER2 status," according to Business Wire. In a survey of 30 U.S. oncologists, 80% called the underlying trial data "clinically meaningful," per FirstWord Pharma.
Pfizer also announced in May that its next-generation 25-valent pediatric pneumococcal vaccine had advanced to Phase 3 trials. Chief Vaccines Officer Annaliesa Anderson said the program aims to cover "up to 90% of disease-causing serotypes" in children under five, according to pharmaphorum. Pfizer pays a $0.43 quarterly dividend, or $1.72 annualized, adding an income component to OP's position.
BMY Insider Sells Shares as OP Buys In
OP Asset Management took 212,727 Bristol Myers Squibb shares for about $12.9 million. But the move came alongside a notable insider sale. On April 1, BMY EVP and CFO David V. Elkins sold 30,000 shares at an average price of $61.67, collecting roughly $1.85 million, according to Investing.com. The sale was executed under a pre-arranged 10b5-1 plan. Elkins has sold over $4.5 million in BMY stock over the past 12 months, with no offsetting insider purchases on record.
BMY is fighting a patent cliff. Key drugs like Eliquis face price pressure from the Inflation Reduction Act. Elkins has previously said the company is "weathering the storm" by leaning on a growth portfolio — including Opdualag and Camzyos — projected to deliver 10–15% sales growth in 2026, per Fierce Pharma. BMY pays a $0.63 quarterly dividend, or $2.52 annualized, which may be part of OP's calculus for holding the stock.
Applied Industrial Bet Signals Manufacturing Rebound Wager
The fund's final new position was 62,945 shares of Applied Industrial Technologies, worth about $16.7 million. AIT is a distributor of industrial components and bearings across North America. Institutional ownership in the stock sits at a striking 93.52%, with major holders including Capital International Investors and Wellington Management. On April 28, AIT raised its full-year fiscal 2026 guidance, citing firming "break-fix" industrial demand across North America, per AIT Investor Relations.
The purchase fits a broader thesis playing out in OP's Q1 filings. The fund also disclosed new stakes in GE Aerospace (185,490 shares, ~$52.6 million) and Cisco Systems (756,453 shares) during the same period, according to Watchlist News. Taken together, the moves suggest OP is building a diversified, high-institutional-ownership portfolio anchored in companies with durable dividends and clear long-term business plans.
Sentiment
Mostly PositivePublishers
50
Articles
26
Reach
76
